Back to top
more

CRISPR Therapeutics (CRSP)

(Delayed Data from NSDQ)

$47.85 USD

47.85
1,061,926

-1.00 (-2.05%)

Updated Aug 16, 2024 04:00 PM ET

After-Market: $47.98 +0.13 (0.27%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (74 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

CRISPR THERAPTC (CRSP) Reports Q2 Loss, Lags Revenue Estimates

CRISPR THERAPTC (CRSP) delivered earnings and revenue surprises of -26.15% and -25.78%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

    Vertex (VRTX) Q2 Earnings and Revenues Surpass Estimates

    Vertex Pharmaceuticals' (VRTX) Q2 rides high on earnings and revenue beat.

      Kevin Cook headshot

      Dopamine and the Weather, Part 2

      How technology changes human behavior and social rules, but not human nature and genetics???yet.

        Are Options Traders Betting on a Big Move in CRISPR Therapeutics (CRSP) Stock?

        Investors in CRISPR Therapeutics AG (CRSP) need to pay close attention to the stock based on moves in the options market lately.

          RedHill Gets Two New Patents for Crohn's Disease Candidate

          RedHill Biopharma (RDHL) announces allowances of two new patents from the United States Patent and Trademark Office and the European Patent Office for its Crohn's disease candidate, RHB-104.

            Nightstar Therapeutics (NITE) in Focus: Stock Moves 6.3% Higher

            Nightstar Therapeutics (NITE) was a big mover last session, as the company saw its shares rise more than 6% on the day.

              Jazz Sells Pain Drug Prialt's Rights to TerSera Therapeutics

              Jazz Pharmaceuticals (JAZZ) signs a definitive contract to sell its Prialt rights to TerSera Therapeutics for a settled amount of $80 million in cash upon its closure.

                Pfizer's Leukemia Candidate Gets Priority Review From FDA

                The FDA grants a priority review to Pfizer's (PFE) NDA for leukemia candidate glasdegib for the first-line treatment of acute myeloid leukemia (AML) in combination with chemotherapy.

                  Has CRISPR THERAPTC (CRSP) Outpaced Other Medical Stocks This Year?

                  Is (CRSP) Outperforming Other Medical Stocks This Year?

                    Kevin Cook headshot

                    Dopamine and the Weather, Part 1

                    How technology changes human behavior and social rules, but not human nature and genetics---yet.

                      Agios Out-Licenses China Rights to Leukemia Drug Tibsovo

                      Agios (AGIO) and CStone Pharmaceticals sign an exclusive collaboration and license agreement for the development and commercialization of its lead pipeline candidate Tibsovo.

                        Zacks Investment Ideas feature highlights: CRISPR, Editas and Intellia

                        Zacks Investment Ideas feature highlights: CRISPR, Editas and Intellia

                          Kevin Cook headshot

                          Knowledge, Certainty, and Destiny: How to Keep Up With Science & Technology

                          Science is bringing the future to you faster every year and this requires a mind wide open.

                            Paratek's Antibiotic Candidate Gets FDA Committee Date

                            Paratek's (PRTK) NDA for its antibiotic candidate, omadacycline, to be reviewed by an FDA advisory committee on Aug 8.

                              Kevin Cook headshot

                              CRISPR Science and Stocks: Knowing Enough to Invest

                              Can you learn enough about the science and the companies to invest with confidence?

                                Amgen Gets EU Nod to Add Survival Data on Blincyto's Label

                                Amgen (AMGN) gets approval from the European Commission to add overall survival (OS) data from the TOWER study on the label of its leukemia drug, Blincyto.

                                  Panel Of Zacks Experts headshot

                                  Top Stock Picks for the Week of June 18, 2018

                                  Tracey Ryniec and Kevin Cook look at a big energy explorer and one of the hot gene editing biotechs.

                                    BioMarin Begins Pediatric Study on Achondroplasia Candidate

                                    BioMarin Pharmaceutical (BMRN) initiates phase II study on vosoritide for the treatment of achondroplasia in infants and children up to five years of age.

                                      Idera Stock Down, Study on Dermatomyositis Candidate Fails

                                      Shares of Idera (IDRA) decline following the failure of a phase II study of its pipeline candidate, IMO-8400, on adult patients with dermatomyositis.

                                        Has CRISPR THERAPTC (CRSP) Outpaced Other Medical Stocks This Year?

                                        Is CRISPR THERAPTC (CRSP) Outperforming Other Medical Stocks This Year?

                                          Biogen Inks Deal With TMS To Acquire Phase II Stroke Asset

                                          Biogen (BIIB) signs a definitive option agreement to buy TMS-007, a phase II candidate, for the treatment of acute ischemic stroke (AIS) from private biotech TMS Co., Ltd.

                                            Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex

                                            Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex

                                              Vertex/CRISPR's Sickle Disease Candidate Put on Hold by FDA

                                              FDA places clinical hold on a Vertex (VRTX) and CRISPR Therapeutics' IND application for CTX001 for the treatment of sickle cell disease.

                                                David Borun headshot

                                                Should You Buy the Dip in CRISPR Therapeutics?

                                                A "Clinical Hold" from the FDA has the shares falling, but is it an opportunity to get in?

                                                  Is CRISPR THERAPTC (CRSP) Stock Outpacing Its Medical Peers This Year?

                                                  Is CRISPR THERAPTC (CRSP) Outperforming Other Medical Stocks This Year?